Economic Analysis and Management Todd Wagner, PhD.

Slides:



Advertisements
Similar presentations
Building a New Payment System: Stakeholder Perspectives on Principles and Elements Robert L. Broadway, FHFMA VP of Corporate Strategy, Bethesda Healthcare.
Advertisements

What You Wanted to Know About Formularies Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School Of Pharmacy.
1 Are you sure your improvements are cost-effective? Edward Broughton, PhD, MPH, PT University Research Co. April 11, 2014
Cost-Effectiveness Using Decision-Analytic Models
HERU is supported by the Chief Scientist Office of the Scottish Government Health Directorates and the University of Aberdeen. The author accepts full.
So You Want to Do Comparative Effectiveness Research? The Nuts and Bolts of CER.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
A METHODOLOGY FOR MEASURING THE COST- UTILITY OF EARLY CHILDHOOD DEVELOPMENTAL INTERVENTIONS Quality of improved life opportunities (QILO)
Economic evaluation considers assessment of intervention effects in economic terms, which is often of greatest interest to fund allocators Intervention.
Journal Club Alcohol and Health: Current Evidence March-April 2006.
Clinical trials methodology group Simon Gates 9 February 2006.
Valuation issues Jan Sørensen, Health Economist CAST – Centre for Applied Health Services Research and Technology Assessment University of Southern Denmark.
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2009.
The Panel on Cost-Effectiveness in Health and Medicine Marthe Gold City University of London 30 October, 2003.
Session 4: Making a case - ROI and business case for tobacco control ARCH Technical Workshop Bali August 2014 Matt Glover Health Economics Research Group.
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
PROJECT EVALUATION. Introduction Evaluation  comparing a proposed project with alternatives and deciding whether to proceed with it Normally carried.
Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.
Budget Impact Analysis and Return on Investment Usa Chaikledkaew, Ph.D.
Chapter 4: Economic Efficiency and Cost Benefit Analysis 1.Economic Efficiency 2.Cost Benefit Analysis.
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Health Systems and the Cycle of Health System Reform
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Disease Management: High Risk Groups Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
1 Cost-effectiveness of improving medical services in low-resource settings Edward Broughton, PhD, MPH, PT University Research Co. May 21, 2014
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
Economics of Implementation: Moving beyond Traditional CEA Mark Smith Paul Barnett VA Health Economics Resource Center.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 1: Introduction Sept 3, 2008.
©The Work Foundation Stephen Bevan Director, Centre for Workforce Effectiveness The Work Foundation & Honorary Professor Lancaster University The Clinical.
Outcomes based approach to measuring the impact of new technology Vikas Arya HSCI 740 Spring 2004 May 22,2004.
EVIDENCE BASED MEDICINE Health economics Ross Lawrenson.
My Own Health Report: Case Study for Pragmatic Research Marcia Ory Texas A&M Health Science Center Presentation at: CPRRN Annual Grantee Meeting October.
Value Based Insurance Design Michael Chernew Oct 10, 2008 Portions of this research were funded by Pfizer and GSK.
Cost-Effectiveness Thresholds Professor of Health Economics
Health Care Costs. How we pay for health care: Private pay Private pay Group health insurance Group health insurance Government sponsored plans Government.
Phaedra Corso, Ph.D. Associate Professor College of Public Health University of Georgia Program Evaluation from an Economic Perspective.
IDENTIFYING KEY AREAS FOR DELIVERY SYSTEM RESEARCH The Challenge and Promise of Delivery System Research: A Meeting of AHRQ Grantees, Experts and Stakeholders.
Cost-Effectiveness of Palliative Team Care For Patients Nearing End-Of-Life Society for Medical Decision Making 36 st Annual Meeting – Miami, Florida October.
Economics of Implementation: Moving beyond Traditional CEA Mark Smith Paul Barnett VA Health Economics Resource Center.
Chapter 2: Economic Systems Section 1
Mohammad Aljawadi PharmD, PhD Clinical Pharmacy Department King Saud University PHCL 431 Sep, 2015.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
MediSave TM : New Software to Calculate the Return on Investment of Tobacco Control Programs Steven S. Foldes, Ph.D. and Anju Joglekar, Ph.D. Blue Cross.
How Can Cost Effectiveness Analysis Be Made More Relevant to U.S. Health Care? Paul G. Barnett, PhD February 29, 2012.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 23: Nov 17, 2008.
PHARMACOECONOMICS Dr. Mohammad Aljawadi, PharmD PhD Department of Clinical Pharmacy King Saud University Aug, 2015 PHCL 431.
Aug 1, Conducting Cost-Effectiveness Analyses of Behavioral Interventions Todd H. Wagner, Ph.D. Mary K. Goldstein, M.D. Mary K. Goldstein, M.D.
Articulating the Value of Consumer Engagement 2 – 3:30 pm ET July 25, 2013.
1 Cost Effectiveness  Jan J.V. Busschbach, Ph.D.  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
How Can Cost Effectiveness Analysis Be Made More Relevant to U.S. Health Care? Paul G. Barnett, PhD December 5, 2012.
Budget Impact Analysis: Methods & Data Mark W. Smith, PhD VA HSR&D Health Economics Resource Center 795 Willow Road (152 MPD), Menlo Park, CA
The Role of Perspective in Economic Evaluation for Cancer Prevention Steven Kymes, Ph.D. Research Associate Professor of Ophthalmology And Visual Sciences.
Flagship Program on Health Sector Reform and Sustainable Financing.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
Health Policy Analysis: Chapters 10, 11 and 14 Nutchanart Bunthumporn Beth Faiman.
HCQ P THE HEALTH CARE QUALITY IMPROVEMENT PARTNERSHIP 1 The Business Case for Quality: A CMS Perspective at the Institute for Quality in Laboratory Medicine,
1 Developing State Specific Evidence on the Costs and Benefits of Early Childhood Education (ECE) Kenneth Troske, Director Center for Business and Economic.
EVALUATION RESEARCH To know if Social programs, training programs, medical treatments, or other interventions work, we have to evaluate the outcomes systematically.
© University of South Wales Royal College of Speech and Language Therapists Outcomes Conference and Hub Launch Belfast, May 1, 2014 Running a tight ship:
Introduction to Economics What do you think of when you think of economics?
Presentation Developed for the Academy of Managed Care Pharmacy
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
Chapter 14 Economic Analysis of Clinical and Managerial Interventions Copyright 2015 Health Administration Press.
Joy Hsu, M.S, M.D., Medical Officer National Center for Environmental Health Division of Environmental Hazards and Health Effects Centers for Disease Control.
RTI International is a trade name of Research Triangle Institute The Costs of SBI: Findings from the literature Presented by Jeremy Bray, Gary.
Payment and Funding Mechanisms
Presentation Developed for the Academy of Managed Care Pharmacy
Presentation transcript:

Economic Analysis and Management Todd Wagner, PhD

TELL ME WHY WE NEED DRUG ELUTING STENTS. AND DON’T GIVE ME THE CONDESCENDING SIMPLE VERSION FOR MANAGERS. I WANT THE FULL TECHNICAL DESCRIPTION. EARLY CIVILIZATIONS HAD NO CONCEPT OF ZERO. GO ON.

Why Would Managers Care? CEA is being used to decide about: –formulary –adoption of new technology –scope of benefits –strategies for management of care –organization of health care

Management Misperceptions Only three types of economic analyses exist –Cost identification– what does X cost –CEA –Return on Investment

Researcher Misperceptions Managers do not understand economics Managers want CEAs A CEA must reflect a societal perspective and lifetime costs and benefits

Basic Rules 1.Set the stage: ask questions & listen 2.Avoid jargon and use the word “no” liberally 3.Build in feedback (interim results) 4.Help the manager: write a good report 5.Help yourself: publish the results

What is the Study Type? Cost identification Cost minimization Cost consequences Cost-effectiveness analysis Cost-benefit analysis Cost-utility analysis Other: efficiency, demand

Return on Investment (ROI) A type cost-benefit analysis Compares input costs to all monetary outputs Time frame is often very short (1 or 2 years) ROI lacks context when talking about health care.

What is the cost? Do we know the cost? How precise are our cost estimates? How do costs vary over time? What affects the cost?

Is Treatment Effective? Is there evidence? How strong is the evidence? A meta analysis may be necessary (

Is a CEA Warranted? Standard care preferred Intervention preferred ? ? CEA is more helpful

Net Benefit Model In many cases, the QALYs are not well known Two approaches: –A net benefit model (Hoch, 2002, Health Economics); capitalize on effectiveness data –A break even analysis; how many QALYs would be required for the intervention to be more cost-effective than than control at $50,000 per QALY?

Comparison Group An intervention or treatment can never be cost effective by itself CEA is always a relative decision –Need at least one comparison group –Treatment X is more cost-effective than Y

Comparison Group (cont.) Important to identify the important comparison group(s) for managers Many clinical trials use placebo controls A CEA with an active comparison may require modeling

Perspective Focus on a payer’s costs/benefits rather than on society’s costs/benefits Congress might be interested in Medicare’s bottom line Excluding patient costs can be important for LTC, RX and some chronic illnesses (e.g., UI)

Transfer Payments Welfare and governmental income assistance programs redistribute money. Transfer payments may be important, although they are not “real” to society. Transfer payments are important for governmental agencies. Always include any administrative fees (usually very small).

Changing Assumptions Managers might want CEA tailored to their situation Consider –Patient population –Clinical risks –Patient volume and costs

Other Outcomes Externalities, such as the effect of substance use treatment on crime may be important Labor force participation and productivity may be particularly important for employers or means tested programs (e.g., Medicaid)

Measurement of Costs VA or non-VA costs? –Pharmaceuticals in the VA are much less expensive than outside the VA –VA salaries tend to be lower –VA inpatient stays tend to be longer Which VA cost data: DSS, HERC national or HERC local?

Main vs Secondary Analyses Wise to conduct an analysis that conforms to the Gold Book, even if this is not the manager’s desire A second analysis can focus on the question outlined for management. –Encourages standardization –Prevents misuse of the results in the future

Use of CEA by Management Q: Is it used? A: Never as the only piece of information, and sometimes not at all. –Hagen MD, Garber AM, Goldie SJ, et al. Does cost-effectiveness analysis make a difference? Lessons from Pap smears. Symposium. Med Decis Making. Jul-Aug 2001;21(4):

Too Quickly, Too Little Managers want the answer immediately, and may not be willing to pay Retrospective studies often take 6 months or more The cost and time frame for a prospective study depend on the level of costing and the length of the study (generally 25% of the total budget)

Managers May Not Know Managers may not know what is wanted (they may be the intermediary) Ask many questions; the Gold Book can be used to identify key issues Try to find out what other stakeholders might want to know

Questions on Management Analyses?